Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Mosquirix

- PMLiVE

GSK’s Ojjaara receives FDA approval to treat myelofibrosis patients with anaemia

Myelofibrosis is a rare blood cancer affecting approximately 25,000 patients in the US

- PMLiVE

GSK invests over $270m in vaccine manufacturing ahead of RSV vaccine launch

The unit will process the company’s vaccines, including Arexvy, Shingrix and Mosquirix

- PMLiVE

GSK discovers strain of bacterium that stops malaria transmission

It is hoped that the discovery could contribute to the eradication of the disease

- PMLiVE

GSK files lawsuit against Pfizer over RSV vaccine patent infringement

The RSV vaccine market is estimated to exceed $5bn and could surpass $10bn by 2030

- PMLiVE

GSK’s Jemperli combination receives FDA approval for endometrial cancer

Approximately 60,000 new cases of endometrial cancer are diagnosed every year in the US

- PMLiVE

GSK’s RSV vaccine Arexvy granted approval by MHRA for older adults

RSV infections in older adults account for about 14,000 hospitalisations each year in the UK

- PMLiVE

GSK’s Jemperli made available to endometrial cancer patients via UK’s early access scheme

Approximately 10,000 new cases of endometrial cancer are reported each year in the UK

- PMLiVE

GSK’s RSV vaccine shows long-term efficacy in late-stage older adults study

Arexvy was recently approved in the EU and US for adults aged 60 years and older

- PMLiVE

GSK’s RSV vaccine approved by European Commission for older adults

RSV infections in older adults account for over 170,000 hospitalisations each year in Europe

- PMLiVE

GSK’s five-in-one meningococcal vaccine candidate shows promise in phase 3 trial

There are no approved vaccines offering simultaneous protection against all five serogroups

- PMLiVE

GSK welcomes Canadian court ruling to dismiss Zantac litigation

The company and other drugmakers have been facing thousands of lawsuits claiming ranitidine caused cancer

- PMLiVE

GSK’s RSV vaccine approved by FDA for older adults

Arexvy is the first RSV vaccine for this age group to be approved anywhere in the world

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links